Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

(Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% ...

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.

Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

Gilead's HIV franchise remains a cornerstone of its business, with the company now focusing on innovative long-acting treatments. The star of this effort is lenacapavir, a potential game-changer ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on GILD stock, giving a Buy rating yesterday. Daina ...

Gilead's HIV franchise remains a cornerstone of its business, with the company now focusing on innovative long-acting treatments. The star of this effort is lenacapavir, a potential game-changer in ...

Gilead Sciences, Inc. (NASDAQ ... The results from the PURPOSE 2 study, which build on the 100% efficacy shown in PURPOSE 1, demonstrate lenacapavir's unmatched clinical profile observed for HIV ...